Forbes featured contributor Paul Irving, chairman of the Milken Institute Center for the Future of Aging and distinguished scholar in residence at the USC Leonard Davis School on the topic of investing in longevity science. Irving interviewed Jim Mellon, an investor and chairman of Juvenescence Ltd. in this first of three interviews honoring “Longevity Innovators,” a project that celebrates improving quality of life globally. According to Mellon, the longevity market is quickly developing, particularly around drugs and gene therapy.
